Table 2.
|
HAART initiation timing during anti-TB therapy |
||||
---|---|---|---|---|---|
No HAART (n = 36) | 0–15 days (n = 110) | 16–30 days (n = 34) | 31–60 days (n = 19) | >60 days (n = 19) | |
Age (yrs) at first TB diagnosis, median [IQR] |
38.8 [32.0–49.6] |
36.8 [31.8–43.6] |
35.5 [31.2–46.7] |
36.6 [33.7–45.1] |
40.4 [29.5–61.3] |
Male |
31 (86.1%) |
107 (97.3%) |
33 (97.1%) |
18 (94.7%) |
17 (89.5%) |
Female |
5 (13.9%) |
3 (2.7%) |
1 (2.9%) |
1 (5.3%) |
2 (10.5%) |
CD4 count(/mm3) at TB diagnosis, median [IQR]$ |
69 [17–370] |
37 [16–87] |
34 [14–62] |
68 [23–134] |
36 [17–94] |
≤50 |
14 (38.9%) |
68 (62.4%) |
26 (74.3%) |
8 (42.15%) |
11 (57.9%) |
51–100 |
7 (19.4%) |
18 (16.4%) |
2 (5.9%) |
5 (26.3%) |
4 (21.1%) |
101–200 |
5 (13.9%) |
11 (10.1%) |
3 (8.6%) |
4 (21.1%) |
1 (5.3%) |
≥200 |
10 (30.8%) |
13 (11.9%) |
3 (8.6%) |
2 (10.5%) |
3 (15.8%) |
Localization of tuberculosis |
|
|
|
|
|
Pulmonary |
16 (44.4%) |
31 (28.5%) |
15 (42.9%) |
6 (31.6%) |
7 (36.8%) |
PTB+ extra-pulmonary |
19 (52.8%) |
72 (65.5%) |
19 (55.9%) |
6 (31.6%) |
12 (63.2%) |
Extra-pulmonary |
1 (2.8%) |
7 (6.4%) |
0 |
7 (36.8%) |
0 |
Laboratory findings |
|
|
|
|
|
Positive AFS smear ± positive MTB Culture |
27 (75.0%) |
85 (78.0%) |
29 (82.9%) |
13 (68.4%) |
12 (63.2%) |
Positive MTB culture only |
9(25.0%) |
25(22.7%) |
5(14.7%) |
6(31.6%) |
7(36.8%) |
HBV(+)#$ |
6(16.7%) |
22(20.2%) |
1(2.9%) |
4(21.1%) |
3(15.8%) |
HCV(+)#$ |
9(25.0%) |
11(10.1%) |
3(8.6%) |
1(5.3%) |
1(5.3%) |
IRIS$ |
– |
41(37.3%) |
12(35.3%) |
2(10.5%) |
2(10.5%) |
Death$ |
23(63.9%) |
19(17.3%) |
5(14.7%) |
0 |
5(26.3%) |
TB-related death$ | 19(52.8%) | 15(13.6%) | 2(5.9%) | 0 | 3(15.8%) |
Data are presented as n (% of the category) unless otherwise indicated.
Abbreviations: IQR interquartile range, PTB pulmonary tuberculosis. AFS acid-fast stain, MTBMycobacterium tuberculosis, IRIS Immune reconstitution inflammatory syndrome, HBV hepatitis B virus infection, HCV hepatitis C virus infection.
*Only included cases with available CD4+ lymphocyte count.
#Only 153 and 141 patients had available HBV and HCV examination results respectively.
$ p <0.01.